Physician profile
Steven A Taylor
NPI 1912052812
$271.57
in general payments reported to CMS, 2019-2025
10 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.00 · 2023: $7.35 · 2024: $109 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $257.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $56.36 | 2024-2025 | Omnipod |
| Tandem Diabetes Care, INC. | $44.13 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Sequel Med Tech, LLC | $34.36 | 2025 | Twiist |
| Regeneron Healthcare Solutions, INC. | $30.81 | 2024 | Dupixent |
| Novo Nordisk INC | $28.20 | 2025 | Ozempic |
| Recordati_rare_diseases_inc. | $21.10 | 2025 | Isturisa |
| Amgen INC. | $19.97 | 2025 | Tepezza |
| Chiesi USA, INC. | $15.29 | 2025 | Mycapssa |
| Medtronic, INC. | $14.00 | 2021 | |
| Beta Bionics, INC. | $7.35 | 2023 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.